泽璟制药注射用ZG006治疗晚期神经内分泌癌纳入突破性治疗品种

Core Viewpoint - ZaiJing Pharmaceutical's investigational product ZG006 has been included in the list of breakthrough therapies by the National Medical Products Administration (NMPA) in China, targeting advanced neuroendocrine carcinoma patients who have previously undergone platinum-based therapy [1] Group 1 - ZG006 is a trispecific antibody drug developed through the company's dual/multi-specific antibody research platform [1] - The product has received clinical trial approval from both the U.S. FDA and China's NMPA [1] - ZG006 has been designated as an orphan drug by the U.S. FDA, indicating its potential significance in treating rare diseases [1]